🇪🇺 DEPREOTIDE in European Union

EMA authorised DEPREOTIDE on 29 November 2000

Marketing authorisation

EMA — authorised 29 November 2000

  • Application: EMEA/H/C/000263
  • Marketing authorisation holder: CIS bio international
  • Local brand name: NeoSpect
  • Indication: This medicinal product is for diagnostic use only.For scintigraphic imaging of suspected malignant tumours in the lung after initial detection, incombination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.
  • Status: withdrawn

Read official source →

DEPREOTIDE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is DEPREOTIDE approved in European Union?

Yes. EMA authorised it on 29 November 2000.

Who is the marketing authorisation holder for DEPREOTIDE in European Union?

CIS bio international holds the EU marketing authorisation.